RNA Formulation Resources

31. Regulatory Readiness Is Built Early 8/3/2026

    Building regulatory readiness early in cell and gene therapy development protects product integrity, prevents costly delays, and secures long-term program viability.

32. Linear Scalability In Turbulent‐Jet Mixing For Nanoparticle Processing 10/14/2025

    Understand how turbulent-jet mixing ensures predictable and reproducible nanoparticle size and uniformity across all scales, accelerating development and regulatory readiness.

33. mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations 6/1/2022

    Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.

34. Ready To Amplify Plasmid (pDNA) In Bacteria? 11/14/2023

    Explore how to use and amplify pDNA from the development of recombinant proteins and viral vectors to advanced bio-therapeutics such as mRNA vaccines.

35. Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs 4/18/2022

    This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.

36. Is Standardization The Key To Scalable CGT? 3/2/2026

    Experts note CGT programs often struggle due to limited operational readiness; early standardization supports scalable, reproducible, regulatory‑ready development and helps prevent late‑stage bottlenecks.

37. Mixing Technology: Linear Scalability And Mixing Precision For Nanoparticle Formulation 8/5/2025

    Find out how you can achieve precise control and linear scalability in nanoparticle formulation with mixing technology that minimizes batch-to-batch variability and simplifies the scale-up process.

38. Process Development Considerations For RNA-LNP Therapeutics 9/13/2022

    Here, we highlight three important process considerations across the RNA-LNP manufacturing workflow which includes limit size behavior, in-line dilution and downstream tangential flow filtration (TFF).

39. Laminar And Turbulent Mixing Techniques For LNP Formulations Scale Up 11/4/2025

    Explore the critical factors in scaling up lipid nanoparticle (LNP) formulation, comparing the advantages and limitations of both laminar (microfluidic) and turbulent (tee and jet) mixing technologies.

40. Oligonucleotide Purification And Synthesis 1/27/2026

    Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.